

Scott H Watterson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2067077/publications.pdf>

Version: 2024-02-01

44
papers

1,318
citations

257450

24
h-index

345221

36
g-index

48
all docs

48
docs citations

48
times ranked

1382
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4 <i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-phenyl)-2-oxoethylamino)-2,3-dihydroquinazolin-4(1 <i>H</i>)-one (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9173-9200.	6.4	111
2	The Total Synthesis of (±)-Ginkgolide B. <i>Journal of the American Chemical Society</i> , 2000, 122, 8453-8463.	13.7	102
3	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3228-3250.	6.4	78
4	(Phenylsulfonyl)allenes as Substrates for Cycloaddition Reactions: Intramolecular Cyclizations onto Unactivated Alkenes. <i>Journal of the American Chemical Society</i> , 1995, 117, 7071-7080.	13.7	73
5	Phenylsulfonyl Ene Allenes as Efficient Precursors to Bicyclic Systems via Intramolecular [2 + 2]-Cycloaddition Reactions. <i>Journal of Organic Chemistry</i> , 2003, 68, 6238-6250.	3.2	66
6	Acridone-Based Inhibitors of Inosine 5'-Monophosphate Dehydrogenase: Discovery and SAR Leading to the Identification of N-(2-(6-(4-Ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419). <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3730-3742.	6.4	50
7	Total Synthesis of (±)-Ginkgolide B. <i>Journal of the American Chemical Society</i> , 1999, 121, 10249-10250.	13.7	48
8	Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. <i>PLoS ONE</i> , 2017, 12, e0181782.	2.5	47
9	Discovery of N-[2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide as a Novel and Potent Inhibitor of Inosine Monophosphate Dehydrogenase with Excellent in Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2127-2130.	6.4	44
10	Peri and stereoselectivity effects in the intramolecular [2+2]-cycloaddition reaction of phenylsulfonyl-substituted allenes. <i>Journal of the American Chemical Society</i> , 1993, 115, 3776-3777.	13.7	43
11	Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2137-2140.	2.2	42
12	Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1273-1276.	2.2	40
13	Small Molecule Antagonist of Leukocyte Function Associated Antigen-1 (LFA-1): Structure-Activity Relationships Leading to the Identification of 6-((5 <i>S</i> ,9 <i>R</i>)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic Acid (BMS-688521). <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3814-3830.	6.4	40
14	Cyclization Reactions of 2,3-Bis(phenylsulfonyl)-1,3-butadiene with Various Carbanions. A [4 + 1] Anionic Annulation Approach to Phenylsulfonyl-Substituted Cyclopentenes. <i>Journal of Organic Chemistry</i> , 1994, 59, 588-596.	3.2	37
15	3-Cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-Activity relationships. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 3557-3560.	2.2	33
16	2,3-Bis(phenylsulfonyl)-1,3-butadiene: A Substrate for Michael Donor/Acceptors in a Novel Synthesis of Fused Cyclopentenes. <i>Journal of Organic Chemistry</i> , 1996, 61, 3829-3838.	3.2	28
17	Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl] moiety. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2059-2063.	2.2	28
18	A New Cyclopentannulation Approach to Bicyclo[3.3.0]octenes Employing a Tandem Michael Addition-[3 + 2]-Anionic Cyclization Sequence. <i>Journal of Organic Chemistry</i> , 1994, 59, 3256-3258.	3.2	27

#	ARTICLE	IF	CITATIONS
19	Novel inhibitors of IMPDH. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 543-546.	2.2	27
20	Identification of novel and potent isoquinoline aminooxazole-Based IMPDH inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1345-1348.	2.2	27
21	Novel guanidine-Based inhibitors of inosine monophosphate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2931-2934.	2.2	26
22	Periodic, Partial Inhibition of $\text{I}\hat{\text{I}}^{\text{B}}$ Kinase $\hat{\text{I}}^2$ -Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 349-360.	2.5	26
23	Novel Tricyclic Inhibitors of $\text{I}\hat{\text{I}}^{\text{B}}$ Kinase. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1994-2005.	6.4	25
24	Novel diamide-Based inhibitors of IMPDH. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 1323-1326.	2.2	24
25	Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P_{1}). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6248-6264.	6.4	22
26	Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase $\hat{\text{I}}$ ($\text{PI3K}\hat{\text{I}}$) Inhibitor for the Treatment of Immunological Disorders. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5193-5208.	6.4	22
27	Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P_{1}): Discovery and SAR of a Novel Isoxazole Based Series. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2820-2840.	6.4	20
28	Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of $\text{I}\hat{\text{I}}^{\text{B}}$ kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2646-2649.	2.2	19
29	Novel amide-based inhibitors of inosine 5 $\hat{\text{I}}^2$ -monophosphate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2879-2882.	2.2	16
30	A survey of cyclic replacements for the central diamide moiety of inhibitors of inosine monophosphate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 3125-3128.	2.2	16
31	Alkylation reactions of 3-(phenylsulfonyl)methyl substituted cyclopentenones. <i>Tetrahedron</i> , 1998, 54, 9651-9666.	1.9	15
32	An Efficient Scale-Up Synthesis of BMS-520, a Potent and Selective Isoxazole-Containing S1P_{1} Receptor Agonist. <i>Organic Process Research and Development</i> , 2016, 20, 989-995.	2.7	15
33	Separation of Bruton $\hat{\text{I}}$'s tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography. <i>Journal of Chromatography A</i> , 2019, 1586, 106-115.	3.7	13
34	Periselectivity in the base-catalyzed intramolecular [2+2]-cycloaddition reaction of 3-phenylsulfonyl-substituted propynes. <i>Tetrahedron Letters</i> , 1995, 36, 4521-4524.	1.4	12
35	Quinolone-Based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 547-551.	2.2	12
36	Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: Synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 383-386.	2.2	11

#	ARTICLE	IF	CITATIONS
37	Novel tricyclic inhibitors of IKK2: Discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7006-7012.		
38	Identification of Tricyclic Agonists of Sphingosine-1-phosphate Receptor 1 (S1P ₁) Employing Ligand-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9837-9854.	6.4	8
39	Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2470-2474.	2.2	6
40	Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2195-2203.	2.8	6
41	A New and Efficient Synthesis of 6-[[5 <i>S</i> ,9 <i>R</i>]-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]nicotinic Acid, a Potent LFA-1/ICAM Inhibitor. <i>Organic Process Research and Development</i> , 2010, 14, 936-938.		
42	Novel Amide-Based Inhibitors of Inosine 5-Phosphate Dehydrogenase.. <i>ChemInform</i> , 2003, 34, no.	0.0	0
43	Novel Inhibitors of IMPDH: A Highly Potent and Selective Quinolone-Based Series. <i>ChemInform</i> , 2003, 34, no.	0.0	0
44	Phenylsulfonyl Ene-Allenes as Efficient Precursors to Bicyclic Systems via Intramolecular [2 + 2]-Cycloaddition Reactions.. <i>ChemInform</i> , 2003, 34, no.	0.0	0